Scholarlink

<p>Stroke is one of the most frequently mistriaged medical emergencies. As a result, significant efforts have been made to identify blood biomarkers that could aid in stroke recognition. Large numbers of studies have reported candidate assays with seemingly high levels of diagnostic performance; however, practices employed in many of these studies could limit generalizability. Thus, in this systematic review and meta-analysis, we sought to clarify whether any of the assays proposed to date have true potential for clinical use. To do this, we quantified the influence of a wide range of possible translational confounds on the diagnostic performance estimates published for 863 single analyte or multianalyte assays investigated for stroke recognition over the past 30 years. We found that up to 56% of&#xa0;the variance in reported levels of diagnostic performance could be directly attributed to latent study design and reporting factors, rather than true differences in the diagnostic capacity of the assays themselves. After correcting for these factors and further considering analytical measurability in the target use environment, not a single assay displayed evidence of clinical utility. Our results clarify the current state of the push towards a viable blood-based stroke diagnostic, and also provide a contextual framework that can be used to more critically evaluate the broader space of molecular biomarker research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systematic review and meta-analysis of stroke blood biomarker data highlights need for more translational research methods

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Christine G. Smothers,
  • Shivam A. Gandhi,
  • Julia H. Chang,
  • Sadia M. Tahir,
  • Jarrett Kelley,
  • Emily Wang,
  • Kareem Fareed,
  • Hannah Mack,
  • Cindy Dong,
  • Madaline Witort,
  • Bethany L. Armentrout,
  • Darynaisha Crawford,
  • Jing Wang,
  • Kara Williams,
  • Zea Bud,
  • Christine Horvat-Davey,
  • Chris Winkelman,
  • Sarah R. Martha,
  • Jon W. Schrock,
  • Agnieszka A. Ardelt,
  • Grant C. O’Connell

摘要

Stroke is one of the most frequently mistriaged medical emergencies. As a result, significant efforts have been made to identify blood biomarkers that could aid in stroke recognition. Large numbers of studies have reported candidate assays with seemingly high levels of diagnostic performance; however, practices employed in many of these studies could limit generalizability. Thus, in this systematic review and meta-analysis, we sought to clarify whether any of the assays proposed to date have true potential for clinical use. To do this, we quantified the influence of a wide range of possible translational confounds on the diagnostic performance estimates published for 863 single analyte or multianalyte assays investigated for stroke recognition over the past 30 years. We found that up to 56% of the variance in reported levels of diagnostic performance could be directly attributed to latent study design and reporting factors, rather than true differences in the diagnostic capacity of the assays themselves. After correcting for these factors and further considering analytical measurability in the target use environment, not a single assay displayed evidence of clinical utility. Our results clarify the current state of the push towards a viable blood-based stroke diagnostic, and also provide a contextual framework that can be used to more critically evaluate the broader space of molecular biomarker research.